Actively Recruiting

Age: 55Years - 85Years
All Genders
NCT06068361

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-03-27

130

Participants Needed

1

Research Sites

155 weeks

Total Duration

On this page

Sponsors

A

Assistance Publique - Hôpitaux de Paris

Lead Sponsor

A

Association des Aidants et Malades à Corps de Lewy (A2MCL)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Dementia with Lewy body disease (DLB) is the second leading cause of degenerative cognitive disorder after Alzheimer's disease (AD). Its variable clinical expression makes diagnosis difficult. To date, there is no validated DLB diagnostic biomarker, despite several biomarkers in development (EEG, MRI, biology). Studies have shown that an improvement in diagnostic performance could be obtained by combining different modalities biomarkers using machine learning. The aim of this research is to identify the best combination of multimodal biomarkers for the diagnosis of DLB (EEG, MRI, biology, cognitive scores), using a machine learning approach applied to a clinical cohort.

CONDITIONS

Official Title

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach

Who Can Participate

Age: 55Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to complete a neuropsychological assessment in French without significant visual or hearing impairment
  • Diagnosis of dementia with Lewy bodies following revised McKeith 2017 criteria or probable Alzheimer's disease according to McKhann 2011 criteria including CSF biomarkers
  • For control participants: MMSE score of 28 or higher, normal MemScreen test, normal brain MRI, and normal neurological exam
  • Age between 55 and 85 years
Not Eligible

You will not qualify if you...

  • Contraindication to MRI
  • Presence of other neurological, psychiatric, toxic, or iatrogenic disorders that explain cognitive impairment or EEG abnormalities
  • Unstable medical conditions that may cause cognitive impairment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre de neurologie Cognitive

Paris, France, France, 75010

Actively Recruiting

Loading map...

Research Team

C

Claire PAQUET, MDPhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here